Lisata Therapeutics, Inc.
US ˙ NasdaqCM ˙ US1280583022

Introduction

This page provides a comprehensive analysis of the known insider trading history of Davidson Michael H.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Davidson Michael H. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:NAMS / NewAmsterdam Pharma Company N.V. Chief Executive Officer, Director 390,441
US:SLN / Silence Therapeutics plc - Depositary Receipt (Common Stock) Director 12,993
US:TENX / Tenax Therapeutics, Inc. Director 2,881
US:CLBS / Caladrius Biosciences Inc Director 209,753
Executive VP & CMO 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Davidson Michael H.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases LSTA / Lisata Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in LSTA / Lisata Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-09-09 CLBS Davidson Michael H. 55,525 1.8000 3,702 27.0000 99,945 133 43.35 60,493 60.53

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LSTA / Lisata Therapeutics, Inc. Insider Trades
Insider Sales LSTA / Lisata Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in LSTA / Lisata Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LSTA / Lisata Therapeutics, Inc. Insider Trades
Insider Purchases NAMSW / NewAmsterdam Pharma Company N.V. - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in LSTA / Lisata Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-08-20 NAMS Davidson Michael H. 5,000 16.2700 5,000 16.2700 81,350 119 26.6100 51,700 63.55
2024-06-20 NAMS Davidson Michael H. 5,000 17.2617 5,000 17.2617 86,308

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NAMSW / NewAmsterdam Pharma Company N.V. - Equity Warrant Insider Trades
Insider Sales NAMSW / NewAmsterdam Pharma Company N.V. - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in LSTA / Lisata Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-26 NAMS Davidson Michael H. 12,258 12,258 15 14.9000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NAMSW / NewAmsterdam Pharma Company N.V. - Equity Warrant Insider Trades
Insider Purchases SLNCF / Silence Therapeutics plc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in LSTA / Lisata Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SLNCF / Silence Therapeutics plc Insider Trades
Insider Sales SLNCF / Silence Therapeutics plc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in LSTA / Lisata Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SLNCF / Silence Therapeutics plc Insider Trades
Insider Purchases TENX / Tenax Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in LSTA / Lisata Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-08-08 TENX Davidson Michael H. 2,500 2,500 186 7.7900

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TENX / Tenax Therapeutics, Inc. Insider Trades
Insider Sales TENX / Tenax Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in LSTA / Lisata Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TENX / Tenax Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Davidson Michael H. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-28 2025-03-26 4 NAMS NewAmsterdam Pharma Co N.V.
Ordinary Shares
S - Sale -12,258 390,441 -3.04
2025-03-28 2025-03-26 4 NAMS NewAmsterdam Pharma Co N.V.
Ordinary Shares
M - Exercise 38,394 402,699 10.54
2025-03-28 2025-03-26 4 NAMS NewAmsterdam Pharma Co N.V.
Ordinary Shares
A - Award 30,992 364,305 9.30
2025-01-07 2025-01-07 4 NAMS NewAmsterdam Pharma Co N.V.
Ordinary Shares
A - Award 123,529 123,529
2025-01-02 3 SLN Silence Therapeutics plc
Ordinary Shares
12,993
2024-08-22 2024-08-20 4 NAMS NewAmsterdam Pharma Co N.V.
Ordinary Shares
P - Purchase 5,000 209,784 2.44 16.27 81,350 3,413,186
2024-08-08 2024-08-08 4 TENX TENAX THERAPEUTICS, INC.
Common Stock
P - Purchase 2,500 2,881 656.17
2024-06-24 2024-06-20 4 NAMS NewAmsterdam Pharma Co N.V.
Ordinary Shares
P - Purchase 5,000 204,784 2.50 17.26 86,308 3,534,920
2023-12-29 3 NAMS NewAmsterdam Pharma Co N.V.
Ordinary Shares
199,784
2023-12-29 3 NAMS NewAmsterdam Pharma Co N.V.
Ordinary Shares
608,779
2022-01-12 2022-01-10 4 CLBS CALADRIUS BIOSCIENCES, INC.
Common Stock
A - Award 65,430 209,753 45.34
2021-06-15 3 TENX TENAX THERAPEUTICS, INC.
Common Stock
96,645
2021-06-15 3 TENX TENAX THERAPEUTICS, INC.
Series B Preferred Stock
512
2021-06-15 2021-06-11 4 TENX TENAX THERAPEUTICS, INC.
Series B Preferred Stock
M - Exercise -512 0 -100.00
2021-06-15 2021-06-11 4 TENX TENAX THERAPEUTICS, INC.
Common Stock
A - Award 512,000 606,645 540.97
2021-06-15 2021-06-10 4 TENX TENAX THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 6,250 6,250
2021-01-12 2021-01-11 4 CLBS CALADRIUS BIOSCIENCES, INC.
Common Stock
A - Award 37,735 144,323 35.40
2020-09-10 2020-09-09 4 CLBS CALADRIUS BIOSCIENCES, INC.
Common Stock
P - Purchase 55,525 106,588 108.74 1.80 99,945 191,858
2020-08-12 2020-07-28 4 CLBS CALADRIUS BIOSCIENCES, INC.
Common Stock
A - Award 51,063 51,063 2.35 119,998 119,998
2013-07-18 2013-07-18 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
D - Sale to Issuer -520,756 0 -100.00
2013-07-18 2013-07-18 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
D - Sale to Issuer -964,587 0 -100.00
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Series A Convertible Preferred Stock
C - Conversion -72,500 0 -100.00
2013-04-17 2013-04-16 4 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
C - Conversion 51,960 964,587 5.69
2013-04-11 3 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
912,627
2013-04-11 3 OMTH Omthera Pharmaceuticals, Inc.
Common Stock
520,756
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)